vs

Side-by-side financial comparison of Diversified Energy Co (DEC) and Moderna (MRNA). Click either name above to swap in a different company.

Moderna is the larger business by last-quarter revenue ($1.0B vs $666.5M, roughly 1.5× Diversified Energy Co). Diversified Energy Co runs the higher net margin — 29.3% vs -19.7%, a 49.0% gap on every dollar of revenue. Diversified Energy Co produced more free cash flow last quarter ($280.0M vs $-880.0M).

DTE Energy is a Detroit-based diversified energy company involved in the development and management of energy-related businesses and services in the United States and Canada. Its operating units include an electric utility serving 2.2 million customers and a natural gas utility serving 1.3 million customers in Michigan.

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

DEC vs MRNA — Head-to-Head

Bigger by revenue
MRNA
MRNA
1.5× larger
MRNA
$1.0B
$666.5M
DEC
Higher net margin
DEC
DEC
49.0% more per $
DEC
29.3%
-19.7%
MRNA
More free cash flow
DEC
DEC
$1.2B more FCF
DEC
$280.0M
$-880.0M
MRNA

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
DEC
DEC
MRNA
MRNA
Revenue
$666.5M
$1.0B
Net Profit
$195.5M
$-200.0M
Gross Margin
79.6%
Operating Margin
37.6%
-25.6%
Net Margin
29.3%
-19.7%
Revenue YoY
-45.4%
Net Profit YoY
-1638.5%
EPS (diluted)
$-0.51

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DEC
DEC
MRNA
MRNA
Q4 25
$666.5M
Q3 25
$499.8M
$1.0B
Q2 25
$600.3M
Q4 24
$966.0M
Q3 24
$1.9B
Q4 23
$2.8B
Q3 23
$1.8B
Q1 23
$1.9B
Net Profit
DEC
DEC
MRNA
MRNA
Q4 25
$195.5M
Q3 25
$171.1M
$-200.0M
Q2 25
$297.7M
Q4 24
$-1.1B
Q3 24
$13.0M
Q4 23
$217.0M
Q3 23
$-3.6B
Q1 23
$79.0M
Gross Margin
DEC
DEC
MRNA
MRNA
Q4 25
Q3 25
79.6%
Q2 25
44.7%
Q4 24
23.5%
Q3 24
72.4%
Q4 23
67.0%
Q3 23
-22.4%
Q1 23
57.5%
Operating Margin
DEC
DEC
MRNA
MRNA
Q4 25
37.6%
Q3 25
36.2%
-25.6%
Q2 25
48.5%
Q4 24
-129.0%
Q3 24
-3.8%
Q4 23
0.2%
Q3 23
-109.9%
Q1 23
-19.7%
Net Margin
DEC
DEC
MRNA
MRNA
Q4 25
29.3%
Q3 25
34.2%
-19.7%
Q2 25
49.6%
Q4 24
-115.9%
Q3 24
0.7%
Q4 23
7.7%
Q3 23
-198.3%
Q1 23
4.2%
EPS (diluted)
DEC
DEC
MRNA
MRNA
Q4 25
Q3 25
$2.14
$-0.51
Q2 25
$3.67
Q4 24
$-2.91
Q3 24
$0.03
Q4 23
$0.63
Q3 23
$-9.53
Q1 23
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DEC
DEC
MRNA
MRNA
Cash + ST InvestmentsLiquidity on hand
$29.7M
$1.1B
Total DebtLower is stronger
$2.7B
Stockholders' EquityBook value
$984.1M
$9.3B
Total Assets
$6.2B
$12.1B
Debt / EquityLower = less leverage
2.76×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DEC
DEC
MRNA
MRNA
Q4 25
$29.7M
Q3 25
$1.1B
Q2 25
$23.7M
Q4 24
$1.9B
Q3 24
$1.6B
Q4 23
$2.9B
Q3 23
$2.9B
Q1 23
$3.4B
Total Debt
DEC
DEC
MRNA
MRNA
Q4 25
$2.7B
Q3 25
Q2 25
Q4 24
Q3 24
Q4 23
Q3 23
Q1 23
Stockholders' Equity
DEC
DEC
MRNA
MRNA
Q4 25
$984.1M
Q3 25
$9.3B
Q2 25
$727.7M
Q4 24
$10.9B
Q3 24
$11.9B
Q4 23
$13.9B
Q3 23
$13.5B
Q1 23
$18.9B
Total Assets
DEC
DEC
MRNA
MRNA
Q4 25
$6.2B
Q3 25
$12.1B
Q2 25
$5.7B
Q4 24
$14.1B
Q3 24
$15.8B
Q4 23
$18.4B
Q3 23
$19.4B
Q1 23
$24.1B
Debt / Equity
DEC
DEC
MRNA
MRNA
Q4 25
2.76×
Q3 25
Q2 25
Q4 24
Q3 24
Q4 23
Q3 23
Q1 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DEC
DEC
MRNA
MRNA
Operating Cash FlowLast quarter
$464.6M
$-847.0M
Free Cash FlowOCF − Capex
$280.0M
$-880.0M
FCF MarginFCF / Revenue
42.0%
-86.6%
Capex IntensityCapex / Revenue
27.7%
3.2%
Cash ConversionOCF / Net Profit
2.38×
TTM Free Cash FlowTrailing 4 quarters
$-1.9B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DEC
DEC
MRNA
MRNA
Q4 25
$464.6M
Q3 25
$-847.0M
Q2 25
$264.1M
Q4 24
$825.0M
Q3 24
$-1.6B
Q4 23
$622.0M
Q3 23
$-1.6B
Q1 23
$-1.2B
Free Cash Flow
DEC
DEC
MRNA
MRNA
Q4 25
$280.0M
Q3 25
$-880.0M
Q2 25
Q4 24
$303.0M
Q3 24
$-1.7B
Q4 23
$402.0M
Q3 23
$-1.7B
Q1 23
$-1.3B
FCF Margin
DEC
DEC
MRNA
MRNA
Q4 25
42.0%
Q3 25
-86.6%
Q2 25
Q4 24
31.4%
Q3 24
-92.2%
Q4 23
14.3%
Q3 23
-95.0%
Q1 23
-71.9%
Capex Intensity
DEC
DEC
MRNA
MRNA
Q4 25
27.7%
Q3 25
3.2%
Q2 25
Q4 24
54.0%
Q3 24
8.1%
Q4 23
7.8%
Q3 23
7.6%
Q1 23
6.1%
Cash Conversion
DEC
DEC
MRNA
MRNA
Q4 25
2.38×
Q3 25
Q2 25
0.89×
Q4 24
Q3 24
-120.46×
Q4 23
2.87×
Q3 23
Q1 23
-15.51×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DEC
DEC

Segment breakdown not available.

MRNA
MRNA

COVID19$971.0M96%
Other Revenue$20.0M2%
Grant$14.0M1%
Collaboration Arrangement Including Arrangements With Affiliate$7.0M1%
License And Royalty$2.0M0%

Related Comparisons